The dynamic role of autophagy and MAPK signaling in determining cell fate under cisplatin stress in osteosarcoma cells
Osteosarcoma (OS) is an aggressive bone malignancy commonly observed in children and
adolescents. Sub-optimal therapy for years has irretrievably compromised the chances of
OS patient survival; also, lack of extensive research on this rare disease has hindered
therapeutic development. Cisplatin, a common anti-tumor drug, is currently an integral part
of treatment regime for OS along with methotrexate and doxorubicin. However, toxicity
issues associated with combination module impede OS therapy. Also, despite the proven …
adolescents. Sub-optimal therapy for years has irretrievably compromised the chances of
OS patient survival; also, lack of extensive research on this rare disease has hindered
therapeutic development. Cisplatin, a common anti-tumor drug, is currently an integral part
of treatment regime for OS along with methotrexate and doxorubicin. However, toxicity
issues associated with combination module impede OS therapy. Also, despite the proven …
The dynamic role of autophagy and MAPK signaling in determining cell fate under cisplatin stress in osteosarcoma cell
R Chowdhury, S Mukherjee - 2017 - dspace.bits-pilani.ac.in
Osteosarcoma (OS) is an aggressive bone malignancy commonly observed in children and
adolescents. Sub-optimal therapy for years has irretrievably compromised the chances of
OS patient survival; also, lack of extensive research on this rare disease has hindered
therapeutic development. Cisplatin, a common anti-tumor drug, is currently an integral part
of treatment regime for OS along with methotrexate and doxorubicin. However, toxicity
issues associated with combination module impede OS therapy. Also, despite the proven …
adolescents. Sub-optimal therapy for years has irretrievably compromised the chances of
OS patient survival; also, lack of extensive research on this rare disease has hindered
therapeutic development. Cisplatin, a common anti-tumor drug, is currently an integral part
of treatment regime for OS along with methotrexate and doxorubicin. However, toxicity
issues associated with combination module impede OS therapy. Also, despite the proven …
以上显示的是最相近的搜索结果。 查看全部搜索结果